

# Mathieu F Chevalier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5077229/publications.pdf>

Version: 2024-02-01

32  
papers

1,428  
citations

471061

17  
h-index

476904

29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

2624  
citing authors

#	ARTICLE	IF	CITATIONS
1	The split personality of regulatory T cells in HIV infection. <i>Blood</i> , 2013, 121, 29-37.	0.6	192
2	ILC2-modulated T cell-tumor-MDSC balance is associated with bladder cancer recurrence. <i>Journal of Clinical Investigation</i> , 2017, 127, 2916-2929.	3.9	176
3	Tumour-derived PGD2 and Nkp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. <i>Nature Communications</i> , 2017, 8, 593.	5.8	175
4	HIV-1-Specific Interleukin-21 CD4 T Cell Responses Contribute to Durable Viral Control through the Modulation of HIV-Specific CD8 T Cell Function. <i>Journal of Virology</i> , 2011, 85, 733-741.	1.5	173
5	The multifaceted immune regulation of bladder cancer. <i>Nature Reviews Urology</i> , 2019, 16, 613-630.	1.9	123
6	The Th17/Treg Ratio, IL-1RA and sCD14 Levels in Primary HIV Infection Predict the T-cell Activation Set Point in the Absence of Systemic Microbial Translocation. <i>PLoS Pathogens</i> , 2013, 9, e1003453.	2.1	91
7	Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization. <i>Frontiers in Immunology</i> , 2019, 10, 622.	2.2	55
8	Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy. <i>European Urology</i> , 2018, 74, 540-544.	0.9	53
9	Level of double negative T cells, which produce TGF- $\beta$ 2 and IL-10, predicts CD8 T-cell activation in primary HIV-1 infection. <i>Aids</i> , 2012, 26, 139-148.	1.0	52
10	Phenotype Alterations in Regulatory T-Cell Subsets in Primary HIV Infection and Identification of Tr1-like Cells as the Main Interleukin 10-Producing CD4+ T Cells. <i>Journal of Infectious Diseases</i> , 2015, 211, 769-779.	1.9	37
11	Epithelial adhesion molecules can inhibit HIV-1-specific CD8+ T-cell functions. <i>Blood</i> , 2011, 117, 5112-5122.	0.6	31
12	Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model. <i>Cancer Immunology Research</i> , 2019, 7, 621-629.	1.6	26
13	Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse. <i>Blood</i> , 2022, 140, 1305-1321.	0.6	23
14	Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer. <i>European Urology</i> , 2017, 71, 854-857.	0.9	22
15	T <sub>H</sub> 1 T-cell subsets in HIV controllers. <i>Aids</i> , 2019, 33, 1283-1292.	1.0	22
16	Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer. <i>OncImmunology</i> , 2017, 6, e1265720.	2.1	19
17	The pro- and anti-tumor role of ILC2s. <i>Seminars in Immunology</i> , 2019, 41, 101276.	2.7	19
18	T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection. <i>Aids</i> , 2014, 28, 1683-1687.	1.0	18

#	ARTICLE	IF	CITATIONS
19	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. <i>Oncolmmunology</i> , 2015, 4, e1029702.	2.1	17
20	CD4 T-Cell Responses in Primary HIV Infection: Interrelationship with Immune Activation and Virus Burden. <i>Frontiers in Immunology</i> , 2016, 7, 395.	2.2	17
21	Local Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. <i>Oncolmmunology</i> , 2015, 4, e1016697.	2.1	11
22	Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. , 2021, 9, e003123.		11
23	Real-world characteristics of T-cell apheresis and clinical response to Atisagenlecleucel in B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 4657-4660.	2.5	11
24	Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 390-398.	0.9	10
25	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. <i>Cancer Discovery</i> , 2022, 12, 958-983.	7.7	10
26	Interleukin-1 receptor antagonist, a biomarker of response to anti-TB treatment in HIV/TB co-infected patients. <i>Journal of Infection</i> , 2017, 74, 456-465.	1.7	9
27	Immunotherapeutic strategies for bladder cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 977-981.	1.4	6
28	Association of Plasma Soluble Vascular Cell Adhesion Molecule-1 and sCD14 With Mortality in HIV-1-Infected West African Adults With High CD4 Counts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 138-145.	0.9	6
29	Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients. <i>European Urology Focus</i> , 2022, 8, 748-751.	1.6	6
30	Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients. <i>European Urology Open Science</i> , 2021, 34, 79-82.	0.2	5
31	Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. , 2021, 9, .		2
32	The early Th17/Treg ratio predicts the immune activation set point in patients with primary HIV infection. <i>Retrovirology</i> , 2012, 9, .	0.9	0